

In the paragraph on page 7, lines 24-26, the text has been amended as follows:

*C3*  
--Figures 10A-D show the results of assays to determine amplification of the DcR3 gene in various lung and colon tumors and in various colon tumor cell lines.---

In the claims:

30. (Amended) The hybridoma cell line 4C4.1.4 deposited as ATCC accession number HB-12573.

31. (Amended) The hybridoma cell line 5C4.14.7 deposited as ATCC accession number HB-12574.

32. (Amended) The hybridoma cell line 11C5.2.8 deposited as ATCC accession number HB-12572.

*C4*  
33. (Amended) The hybridoma cell line 8D3.1.5 deposited as ATCC accession number HB-12571.

34. (Amended) The hybridoma cell line 4B7.1.1 deposited as ATCC accession number HB-12575.

35. (Amended) The 4C4.1.4 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number HB-12573.

36. (Amended) The 5C4.14.7 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number HB-12574.

37. (Amended) The 11C5.2.8 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number HB-12572.

38. (Amended) The 8D3.1.5 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number HB-12571.

C4  
39. (Amended) The 4B7.1.1 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number HB-12575.

Please amend claim 67 to read as follows:

C5  
67. (Amended) An isolated anti-DcR3 antibody which (a) binds to a DcR3 polypeptide consisting of amino acids 1 to 215 or amino acids 1 to 300 of Fig. 1 (SEQ ID NO:1) and (b) inhibits binding of Fas ligand to the DcR3 polypeptide of (a).

68. The antibody of claim 67 wherein said antibody is a monoclonal antibody.

69. The antibody of claim 68 wherein said antibody is a chimeric antibody.

70. The antibody of claim 68 wherein said antibody comprises a Fab fragment.

71. The antibody of claim 68 wherein said antibody is a monovalent antibody.

72. The antibody of claim 68 wherein said antibody is a human antibody.

73. The antibody of claim 68 wherein said antibody is expressed in a recombinant host cell selected from the group consisting of a CHO cell, yeast cell and E. coli.

74. The antibody of claim 67 wherein said antibody further inhibits binding of LIGHT ligand to the DcR3 polypeptide of (a).

Please amend claim 75 to read as follows:

C6  
75. (Amended) An isolated anti-DcR3 antagonist antibody which (a)

*C6*

binds to a DcR3 polypeptide consisting of amino acids 1 to 215 or amino acids 1 to 300 of Fig. 1 (SEQ ID NO:1), (b) blocks binding of Fas ligand to the DcR3 polypeptide of (a), and (c) neutralizes inhibitory effect of the DcR3 polypeptide of (a) on Fas ligand activity in one or more mammalian cells.

76. The antibody of claim 75 wherein said antibody neutralizes inhibitory effect of the DcR3 polypeptide of (a) on Fas ligand-induced apoptosis in one or more mammalian cells.

77. The antibody of claim 76 wherein said antibody neutralizes inhibitory effect of the DcR3 polypeptide of (a) on Fas ligand-induced apoptosis in one or more mammalian cancer cells.

78. The antibody of claim 77 wherein said mammalian cancer cells are colon cancer cells or lung cancer cells.

79. The antibody of claim 75 wherein said antibody is a monoclonal antibody.

80. The antibody of claim 79 wherein said antibody is a chimeric antibody.

81. The antibody of claim 79 wherein said antibody comprises a Fab fragment.

82. The antibody of claim 79 wherein said antibody is a monovalent antibody.

83. The antibody of claim 79 wherein said antibody is a human antibody.

84. The antibody of claim 79 wherein said antibody is expressed in a recombinant host cell selected from the group consisting of a CHO cell, yeast cell and E. coli.

Please amend claim 85 to read as follows:

85. (Amended) An isolated anti-DcR3 antibody which binds to a DcR3 polypeptide comprising amino acids 1 to 215 of Fig. 1 (SEQ ID NO:1) and binds to the same DcR3 polypeptide epitope as the epitope to which the 4C4.1.4 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number HB-12573 binds.

{Please amend claim 86 to read as follows:}

86. (Amended) An isolated anti-DcR3 antibody which binds to a DcR3 polypeptide comprising amino acids 1 to 215 of Fig. 1 (SEQ ID NO:1) and binds to the same DcR3 polypeptide epitope as the epitope to which the 5C4.14.7 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number HB-12574 binds.

C7

{Please amend claim 87 to read as follows:}

87. (Amended) An isolated anti-DcR3 antibody which binds to a DcR3 polypeptide comprising amino acids 1 to 215 of Fig. 1 (SEQ ID NO:1) and binds to the same DcR3 polypeptide epitope as the epitope to which the 11C5.2.8 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number HB-12572 binds.

{Please amend claim 88 to read as follows:}

88. (Amended) An isolated anti-DcR3 antibody which binds to a DcR3 polypeptide comprising amino acids 1 to 215 of Fig. 1 (SEQ ID NO:1) and binds to the same DcR3 polypeptide epitope as the epitope to which the 8D3.1.5 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number HB-12571 binds.

binds.

{Please amend claim 89 to read as follows:}

C7  
89. (Amended) An isolated anti-DcR3 antibody which binds to a DcR3 polypeptide comprising amino acids 1 to 215 of Fig. 1 (SEQ ID NO:1) and binds to the same DcR3 polypeptide epitope as the epitope to which the 4B7.1.1 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number HB-12575 binds. --